A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|4|2|183-189

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.4, Iss.2, 2004-03, pp. : 183-189

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibiting Breast Cancer Progression by Exploiting TGF&bgr; Signaling

By  

Current Drug Targets, Vol. 11, Iss. 9, 2010-09 ,pp. : 1089-1102

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel response, toxicity related to dose in breast cancer

By  

Inpharma, Vol. 1, Iss. 1562, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions

By  

Current Molecular Pharmacology, Vol. 7, Iss. 1, 2014-04 ,pp. : 4-21

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 13, Iss. 2, 2014-05 ,pp. : 105-111

Bentham Science Publishers

Access to resources Recommend Favorite

HT-related decrease in breast density may cause breast cancer

By  

Reactions Weekly, Vol. 1, Iss. 1151, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite